ISRG at a glance
Intuitive Surgical (ISRG, SEC CIK 1035267) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on July 27, 2026 and Form 4 insider filings as recently as September 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Intuitive Surgical (ISRG) reported revenue of $10.1 billion (up 20.5% from FY2024) and net income of $2.9 billion. Diluted EPS was $7.87.
- As of June 30, 2026, 58 institutional investment managers tracked by SignalX reported holding Intuitive Surgical (ISRG) shares worth $55.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Widman Fredrik on September 15, 2026 of 546 shares at $374.44 per share.
- In the last 90 days, ISRG insiders reported 0 open-market purchases ($0) and 20 open-market sales ($5.0M) on Form 4, a net sale of $5.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $10.1B
- +20.5% vs prior year
- Insiders · 90 days
- 0 buys · 20 sells
- Net −$5.0M
- 13F holders
- 58 funds
- $55.9B · +2 vs prior quarter
- Latest 8-K
- Jul 27, 2026
- Item 5.03
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Tariffs increased cost of revenues by $63.0M in 2025; ongoing tariff impact expected to rise in 2026
- Installed base: 1,231 da Vinci 5 systems, 377 da Vinci SP systems as of Dec 31, 2025
- Numerous regulatory clearances in 2024-2026 including FDA approvals for da Vinci 5 multi-port & SP systems for expanded procedures
- Supply chain stress noted in Q4 2025 did not materially impact operations; elevated interest rates and tariff inflation are risks
- Expansion in China constrained by government quotas and provincial pricing limits; pricing pressure and procedural volume impact possible
Business Overview
- Core business: robotic-assisted minimally invasive surgical systems with integrated instruments, accessories, learning, and digital solutions
- New product emphasis: launched da Vinci 5 system with force feedback, 10,000x computing power of Xi, and My Intuitive+ digital subscription package
- Strategic shift: expanded digital ecosystem with My Intuitive app, SimNow VR simulator, Case Insights analytics, and Intuitive Hub edge computing
- Quantitative metric: da Vinci 5 features integrated electrosurgical unit, Integrated Table Motion; new 8mm SureForm 30 Curved-Tip stapler introduced
- Noteworthy fact: first commercial adoption of augmented reality 3D modeling service for pre-operative planning in kidney, prostate, lung, rectal procedures
Risk Factors
- UK medical device regulatory changes, new post-market rules effective June 16, 2025, with additional rules expected in 2026 potentially delaying UK market approval
- China anti-corruption campaign in healthcare since July 2023 causing tender cancellations, reducing system placements in 2025 versus expectations
- Tariffs on imports from Mexico (manufacturing base for majority of instruments) imposed in 2025 increasing product costs and reducing gross margins
- Competition from Medtronic plc and Johnson & Johnson focusing on robotic-assisted surgical systems and alternative therapies reducing market share
- Exposure to US Foreign Corrupt Practices Act, UK Bribery Act compliance risks in OUS operations with increasing business in China and complex local laws
AI summary of the ISRG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Tariffs and trade measures $20.8M in quarterly cost of revenue
- IEEPA tariff refunds $35.9M, reducing quarterly cost of revenue
- Da Vinci 5 installed base 1,710 systems, including 136 outside the U.S.
- Headwinds: tariffs, supply constraints, hospital financial pressure, elevated interest rates, and elongated regulatory timelines
Risk Factors
- Newly highlighted third-party instrument and service risk, involving remanufactured accessories and unauthorized da Vinci or Ion maintenance
- Revenue risk from lower-priced third-party instruments and accessories affecting instrument and accessory sales
- Patient-safety and reputation exposure from third-party products causing injuries or malfunctioning
- Regulatory risk from laws governing third-party interaction with company systems
AI summary of the ISRG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Bylaws strengthen advance-notice and disclosure requirements for shareholder nominations and proposals
- Company may disregard noncompliant universal-proxy nominees, including solicitations failing the SEC’s 67% requirement
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Press release issued July 16, 2026, with financial results in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 revenue $2.89B, up 19%, with instruments/accessories reaching $1.73B on 15% da Vinci procedure growth
- Da Vinci placements rose to 468 from 395, including 246 da Vinci 5 systems, strengthening future recurring consumables revenue
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Henry L. Charlton becomes Senior Vice President of Global Business Operations effective July 1, 2026
- Taylor Patton succeeds Charlton as Chief Commercial and Marketing Officer
AI summaries of ISRG 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ISRG
Don't miss the next ISRG filing
- Alerts as it files. A push when ISRG files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ISRG, by share count.
- Ask anything. An AI agent that reads every ISRG filing and answers with sources.
ISRG alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Widman Fredrik | Sell | Sep 15, 2026 | 546 | $374.44 |
| Widman Fredrik | M | Sep 15, 2026 | 543 | $109.49 |
| Widman Fredrik | Sell | Sep 15, 2026 | 543 | $374.44 |
| Widman Fredrik | M | Sep 15, 2026 | 546 | - |
| Widman Fredrik | M | Sep 15, 2026 | 543 | - |
| Widman Fredrik | M | Sep 15, 2026 | 546 | $79.64 |
| Brosius Mark | Sell | Sep 11, 2026 | 25 | $365.79 |
| Brosius Mark | Sell | Sep 10, 2026 | 23 | $347.66 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $8.4B | $10.1B |
| Gross Profit | $4.7B | $5.6B | $6.6B |
| Operating Income | - | $2.3B | $2.9B |
| Net Income | $1.8B | $2.3B | $2.9B |
| Gross Margin | - | 67.5% | 66.0% |
| Op. Margin | - | 28.1% | 29.3% |
| Net Margin | - | 27.8% | 28.4% |
| Balance Sheet | |||
| Total Assets | $15.4B | $18.7B | $20.5B |
| Equity | - | $16.4B | $17.8B |
| ROE | - | 14.1% | 16.0% |
| Per Share | |||
| EPS | $5.03 | $6.42 | $7.87 |
| Cash Flow | |||
| Operating CF | - | $2.4B | $3.0B |
Source: XBRL data in Intuitive Surgical (ISRG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ISRG share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 58 | $55.95B |
| Q1 2026 | 56 | $65.63B |
| Q4 2025 | 54 | $83.16B |
| Q3 2025 | 54 | $64.56B |
| Q2 2025 | 52 | $81.15B |
| Q1 2025 | 48 | $51.66B |
| Q4 2024 | 47 | $43.73B |
| Q3 2024 | 41 | $19.45B |
- Invesco Ltd+653.1K (+6%)
- Two Sigma Investments+573.8K (+41%)
- Morgan Stanley+502.5K (+8%)
- Goldman Sachs Group+440.6K (+18%)
- Renaissance Technologies LLC+365.0K (+262%)
- T. Rowe Price Group−1.26M (-10%)
- FMR LLC (Fidelity)−1.23M (-22%)
- Citadel Advisors LLC−885.9K (-65%)
- Millennium Management−497.0K (-55%)
- JPMorgan Chase & Co−362.9K (-8%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 410 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ISRG filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 16, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 9, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 29, 2026 | - | - | - |
| 8-K | Jul 27, 2026 | - | Analysis | - |
| 10-Q | Jul 21, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 16, 2026 | - | Analysis | - |
| 4 | Jul 13, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | May 28, 2026 | - | Analysis | |
| 4 | May 22, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 4 | May 11, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 4 | May 1, 2026 | - | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ENOV · Enovis CORPOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
ISRG SEC filings: frequently asked questions
Are ISRG insiders buying or selling?
In the last 90 days, Intuitive Surgical (ISRG) officers, directors and 10% owners reported no open-market purchases and 20 open-market sales worth $5.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ISRG stock?
As of June 30, 2026, the largest Intuitive Surgical (ISRG) holders among the 13F filers tracked by SignalX were BlackRock ($11.9 billion), Vanguard Capital Management LLC ($9.2 billion), State Street Corp ($6.4 billion), Invesco Ltd ($4.7 billion), T. Rowe Price Group ($4.5 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ISRG's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Intuitive Surgical (ISRG) reported revenue of $10.1 billion (up 20.5% from FY2024) and net income of $2.9 billion. Diluted EPS was $7.87. The figures come from the XBRL data in the 10-K.
What are the main risks in ISRG's latest 10-K?
In the 10-K filed February 3, 2026, Intuitive Surgical (ISRG) flagged: UK medical device regulatory changes, new post-market rules effective June 16, 2025, with additional rules expected in 2026 potentially delaying UK market approval. China anti-corruption campaign in healthcare since July 2023 causing tender cancellations, reducing system placements in 2025 versus expectations. (AI summary of the Risk Factors section.)
What did ISRG report in its latest 8-K?
Intuitive Surgical (ISRG) filed an 8-K on July 27, 2026 reporting Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Bylaws strengthen advance-notice and disclosure requirements for shareholder nominations and proposals.
What are the latest ISRG SEC filings?
Intuitive Surgical (ISRG) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on July 21, 2026, an 8-K current report on July 27, 2026 and a Form 4 insider filing on September 16, 2026.
What is ISRG's SEC CIK number?
Intuitive Surgical (ISRG)'s SEC Central Index Key (CIK) is 1035267. EDGAR lists every ISRG filing under that number.
Ask anything about ISRG
The research agent reads ISRG's filings, financials, insider trades and 13F holders, then answers with sources.